ENDRA Life Sciences Inc. - Form 8-K Summary
Business Context and Reporting Period
ENDRA Life Sciences Inc., an emerging growth company incorporated in Delaware, filed this Current Report on Form 8-K on March 26, 2020. The filing serves to announce the company's financial results for the quarter and full year ended December 31, 2019, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These figures are referenced as being contained within the press release (Exhibit 99.1) but are not detailed in the body of this 8-K filing.
Material Changes
No specific material changes versus prior periods are quantified in this document. The filing solely acts as a notification that the results for the period ended December 31, 2019, have been issued.
Guidance, Outlook, and Risks
This filing does not provide specific guidance, outlook, management commentary, or risk factors. It explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor incorporated by reference except as expressly set forth.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated March 26, 2020) for actual financial figures for Q4 and FY 2019.
- Verify the company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.
- Confirm the trading symbols (NDRA for Common Stock, NDRAW for Warrants) on The Nasdaq Stock Market LLC.
- Note that the financial data in this specific 8-K text is not legally "filed" under Section 18 of the Exchange Act.